Rehabilitation Robots MarketSize, Share & Industry Analysis, 2026-2034By TypeBy Robotic StructureBy ExtremityBy Mobility ModeBy ApplicationBy Patient Age GroupBy Control TechnologyBy Actuation TechnologyBy ComponentBy End UserBy Sales Channel
Full title & scope — all 11 axes with their segments
Rehabilitation Robots Market Size, Share & Industry Analysis, By Type (Therapy Robots, Assistive Robots, Exoskeletons, Telerehabilitation Robots, Brain-Computer Interface Robots), By Robotic Structure (End-Effector Robots, Exoskeleton Robots, Hybrid Robots), By Extremity (Upper Extremity, Lower Extremity, Full Body), By Mobility Mode (Stationary Systems, Overground Systems, Treadmill-Based Systems, Wearable Systems), By Application (Stroke, Spinal Cord Injury, Traumatic Brain Injury, Cerebral Palsy, Multiple Sclerosis, Parkinson's Disease, Orthopedic and Sports Injuries, Others), By Patient Age Group (Adult, Pediatric, Geriatric), By Control Technology (Electromyography (EMG)-Controlled, Brain-Computer Interface-Controlled, Force and Torque Sensor-Based, Joystick or Manual Control, AI-Adaptive Control), By Actuation Technology (Electric Actuators, Pneumatic Actuators, Hydraulic Actuators, Cable-Driven and Soft Actuators), By Component (Hardware, Software, Services), By End User (Hospitals, Rehabilitation Centers, Specialty Clinics, Home Care Settings, Research and Academic Institutes, Sports and Wellness Centers), By Sales Channel (Direct Sales, Distributors, Online Channels, Leasing and Rental), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The size was built upward from annual unit shipments of rehabilitation robots by type, the installed base of clinical systems and wearable devices, and the realised price per unit after discounts, service contracts and leasing arrangements. Therapy robots and exoskeletons were sized separately because their price points and purchase cycles differ widely, and software and service revenue was added on top of the installed base. The build was then checked against disclosed segment revenue from listed suppliers and against customs and procurement records for robotic medical devices. Where the check and the build disagreed, the unit and price assumptions were revisited and corrected; the disclosed revenue was not averaged into the result.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target the roles that decide or influence a purchase: rehabilitation physicians and physiatrists, heads of physiotherapy and occupational therapy departments, hospital procurement and biomedical engineering leads, reimbursement and coding specialists, distributors that install and service systems, and regulatory affairs and product managers at manufacturers. Sampling emphasises North America, Western Europe, Japan, China and South Korea, where most systems are installed, with lighter coverage of the Gulf states and Brazil, where adoption is earlier and purchases are concentrated in a few large centres.
Desk research rests on device clearance and registration records, including the FDA 510(k) and De Novo databases, EU certificate listings, Japan's PMDA approvals and China's NMPA registry. Procurement was read from public tender notices and customs data under the HS codes for orthopaedic appliances and machinery with individual functions. Supplier annual reports and stock exchange filings supply segment revenue and unit commentary, Medicare coding listings for powered exoskeletons inform reimbursement assumptions, and WHO health estimates and national stroke registries provide the patient pools. Clinical trial registries show where new indications are heading.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from patient volumes in stroke, spinal injury and neurological disease, therapist availability, the number of facilities able to afford robotic systems, and the pace at which wearable and home-use devices move from trial to routine care. Prices are assumed to ease slowly as production scales, while software and service income grows with the installed base. Asia Pacific is forecast to gain share as hospital capacity expands. For the forecast to hold, reimbursement must widen beyond the few markets that cover exoskeletons today, clinical studies must keep showing recovery benefits, and component costs must keep falling.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were back-tested against recorded growth in supplier revenue and installed units from 2020 to 2025, and the split between segments was reviewed with clinicians and procurement contacts to confirm that the shift toward wearable and remote systems matches what facilities are buying. Sensitivities were run on average selling price, annual unit placements, the share of home-use sales and the rate at which new reimbursement codes are granted. The sum of driver contributions less restraint reductions was reconciled with the change in revenue between the base year and the final forecast year.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
The estimate is firmest for therapy robots and lower limb exoskeletons in the United States, Germany and Japan, where clearances, tenders and supplier filings give a clear record of placements. It is weakest for telerehabilitation, brain-computer interface systems and home leasing, where reporting is thin and products are still moving from pilot to routine use. The base year total carries a wide band because publishers define the market differently. A change in reimbursement policy, a slower hospital capital cycle or the failure of home devices to show clinical benefit would force a downward revision.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Rehabilitation Robots Market projected to reach?
USD 6.72 USD Billion by 2034, CAGR 16.51%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 38% of global revenue through 2034.
05Which segment leads the market?
Therapy Robots is the largest line by type, at 38% of revenue in 2025.
06Who are the key companies profiled?
DIH Holding US, Inc. (Hocoma), Ekso Bionics Holdings, Inc., ReWalk Robotics Ltd. (Lifeward), Cyberdyne Inc., Fourier Intelligence Co., Ltd., Bionik Laboratories Corp., Myomo, Inc., Hocoma AG, Toyota Motor Corporation, Honda Motor Co., Ltd., Panasonic Holdings Corporation, Parker Hannifin Corporation, Bioness Inc., Instead Technologies Ltd., Motorika Medical Ltd., Barrett Technology, LLC, Tyromotion GmbH, Reha Technology AG, Kinova Inc., Wandercraft SAS, Harmonic Bionics, Inc., Gogoa Mobility Robots S.L., Neofect Co., Ltd., AlterG, Inc., Ottobock SE & Co. KGaA, Technaid S.L., Rehab-Robotics Company Limited, Shenzhen Milebot Robotics Co., Ltd.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.